trending Market Intelligence /marketintelligence/en/news-insights/trending/9lfys5chiquoh1m6ptjhma2 content esgSubNav
In This List

BrainStorm Cell Therapeutics appoints board member

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


BrainStorm Cell Therapeutics appoints board member

Brainstorm Cell Therapeutics Inc. added Anthony Polverino to its board.

The biopharmaceutical executive has more than 25 years industry experience and is serving as the interim chief scientific officer of Kite Pharma Inc., which was acquired by Gilead Sciences Inc. in an $11.9 billion deal.

Prior to joining Kite in 2015, he served as the executive director of Amgen Inc.'s therapeutic innovation unit.

Hackensack, N.J.-based BrainStorm Cell is developing NurOwn to improve patient function in patients with amyotrophic lateral sclerosis, or ALS, a neurodegenerative disease that affects muscles in the body. This results in difficulty speaking, swallowing and eventually breathing.